文献速递乳腺病理

乳腺癌病理中免疫组化新用途:判读与陷阱

Novel uses of immunohistochemistry in breast pathology: interpretation and pitfalls.
PubMed 文献 · Mod Pathol · 2020-10-27

该综述阐述免疫组化在乳腺癌诊断中的新应用与判读要点。GATA3与Sox10有助于识别三阴性乳腺癌,但Sox10可标记三阴性乳腺癌与转移性黑色素瘤需加pan-cytokeratin鉴别。MYB、pan-TRK、突变IDH2分别作为腺样囊性癌、分泌性癌、TCCRP的分子替代标志物,PD-L1判读标准在乳腺癌中不同。

要点

  • GATA3与Sox10辅助识别三阴性乳腺癌,但Sox10与S-100可同时标记三阴性乳腺癌和黑色素瘤。
  • 鉴别三阴性乳腺癌与转移性黑色素瘤时须加pan-cytokeratin免疫组化。
  • MYB、pan-TRK、突变IDH2分别作为腺样囊性癌、分泌性癌、TCCRP的分子替代标志物。

核心结论

  • 新型免疫组化提供额外诊断工具与生物标志物,改善乳腺病理诊断与患者管理。

主要发现

  • GATA3与Sox10对三阴性乳腺癌尤其有用,后者常对其他乳腺分化标志物阴性。
  • Sox10与S-100可同时标记三阴性乳腺癌与转移性黑色素瘤,是主要诊断陷阱。
  • MYB用于腺样囊性癌、pan-TRK用于分泌性癌、突变IDH2用于TCCRP作为分子改变替代标志物。
  • PD-L1免疫组化是乳腺癌免疫治疗的新兴但不完美的生物标志物,其检测参数与评分标准在乳腺癌中不同于其他肿瘤类型。

关键数值与推荐

  • 鉴别三阴性乳腺癌与转移性黑色素瘤时应始终包含pan-cytokeratin免疫组化。
  • 乳腺癌PD-L1免疫组化的检测参数与评分标准不同于其他肿瘤类型。

临床怎么用

  • 在三阴性乳腺癌诊断中联合使用GATA3与Sox10,并警惕Sox10阳性黑色素瘤可能。
  • 对腺样囊性癌、分泌性癌、TCCRP可分别采用MYB、pan-TRK、突变IDH2免疫组化辅助分型。
  • 乳腺癌PD-L1判读需采用乳腺癌专用评分标准,不能套用其他瘤种标准。

局限性

  • 没有单一免疫组化标记具有完美敏感性与特异性。
  • PD-L1免疫组化作为乳腺癌免疫治疗生物标志物尚不完美。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunohistochemistry is an essential component of diagnostic breast pathology. The emergence of novel assays and applications is accompanied by new interpretation criteria and potential pitfalls. Immunohistochemistry assists in supporting breast origin for primary or metastatic carcinomas and identifying non-mammary metastases to the breast; however, no single immunostain is perfectly sensitive nor specific. GATA3 and Sox10 are particularly useful immunostains to identify triple negative breast carcinoma, which are often negative for other markers of mammary differentiation. Sox10 labeling is a major potential diagnostic pitfall, as Sox10 and S-100 label both triple negative breast carcinoma and metastatic melanoma; a pan-cytokeratin immunostain should always be included for this differential diagnosis. Novel immunohistochemistry serves as surrogates for the molecular alterations unique to several of special-type breast carcinomas, including the use of MYB in adenoid cystic carcinoma, pan-TRK in secretory carcinoma, and mutant IDH2 in tall cell carcinoma with reversed polarity (TCCRP). In addition, PD-L1 immunohistochemistry is an emerging, albeit imperfect, biomarker for breast cancer immunotherapy, with different assay parameters and scoring criteria in breast carcinoma compared to other tumor types. The expanding repertoire of novel immunohistochemistry provides additional diagnostic tools and biomarkers that improve diagnostic breast pathology and patient care.

来源:Mod Pathol,查看原文。版权归原作者所有。

引用

  1. Cimino-Mathews A. Novel uses of immunohistochemistry in breast pathology: interpretation and pitfalls. Mod Pathol. 2020. PMID: 33110239. doi:10.1038/s41379-020-00697-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。